Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

Hasbani Follows up the Death of Farah Kassab and Issues Two Decisions and Two Letters to the General Prosecution and the Order of Physicians

 
The Information Office of Deputy Prime Minister Health Minister Ghassan Hasbani issued the following statement:
 
In the context of following up the death of Farah Kassab after she underwent a cosmetic surgery in a specialized hospital in cosmetic surgeries,
 
Health Minister Ghassan Hasbani took the following actions:
 
  1. The issuance of a decision on the prevention of  surgical operations that require a general anesthetic in day hospitals or other cosmetic surgery clinics.
  2. The issuance of a decision on the prevention of  surgical operations that require a general anesthetic in Dr. Nader Saab hospital specialized in cosmetic surgery.
  3. The issuance of a letter to the Public Prosecutor to investigate into the death of Farah Kassab.
  4. The issuance of a letter to the Lebanese Order of Physicians in Beirut to conduct necessary investigations into the death of Farah Kassab, and give the Order a period of two weeks to clarify some technical medical points and answer questions asked by Health Minister concerning the death of the said woman.
 
These steps came to complete the immediate oral decision of Health Minister Ghassan Hasbani to cease operations in the said clinic after the woman's death, and the written decision issued Friday 2 June 2017 which stipulates the following:
 
  1. Surgeries that may cause complications that require intensive care like liposuction and other surgeries shall not performed in places other than specialized hospitals which include an intensive care division that holds a license form Health Ministry in accordance with due process.
  2. The doctor should explain to the patient the risks of the surgery, including the plastic surgery, and ask the patient to sign the Patient Right Form and the informed consent.
    5
    ...
ATC Name B/G Ingredients Dosage Form Price
L04AA29 TRIJAN G Tofacitinib - 10mg 10mg Tablet, film coated 84,793,962 L.L
N06AB10 TIOPRAM G Escitalopram (oxalate) - 10mg 10mg Tablet, film coated 671,921 L.L
C08CA01 TORANS G Amlodipine (besylate) - 10mg 10mg Tablet 716,716 L.L
H03BB02 THYROZOL B Methimazole (Thiamazole) - 10mg 10mg Tablet, film coated 326,554 L.L
C09AA05 TRITACE B Ramipril - 10mg 10mg Tablet 689,391 L.L
S01FA06 TROPICIL TOP G Tropicamide - 10mg/ml 10mg/ml Drops solution 200,233 L.L
L01FX24 TECVAYLI BioTech Teclistamab - 10mg/ml 10mg/ml Injectable solution L.L
N03AX18 TREPADIO G Lacosamide - 10mg/ml 10mg/ml Syrup 948,753 L.L
L01FX24 TECVAYLI BioTech Teclistamab - 10mg/ml 10mg/ml Injectable solution 95,166,436 L.L
B01AC17 TIROPREST G Tirofiban - 12.5mg/50ml 12.5mg/50ml Injectable concentrate for solution 18,279,605 L.L
L01FF05 TECENTRIQ BioTech Atezolizumab - 1200mg 1200mg Injectable concentrate for solution L.L
L01FF05 TECENTRIQ BioTech Atezolizumab - 1200mg 1200mg Injectable concentrate for solution 375,054,619 L.L
L01FF05 TECENTRIQ BioTech Atezolizumab - 1200mg 1200mg Injectable concentrate for solution 375,054,619 L.L
C02KX01 TRACTAN G Bosentan (monohydrate) - 125mg 125mg Tablet, film coated 47,747,570 L.L
R01AD08 TICANASE G Fluticasone propionate - 50mcg/actuation 12g/Bottle Spray, suspension 405,840 L.L
L04AA31 TERAGIO G Teriflunomide - 14mg 14mg Tablet L.L
L04AA31 TERAGIO G Teriflunomide - 14mg 14mg Tablet 49,451,224 L.L
L04AA31 TERAGIO G Teriflunomide - 14mg 14mg Tablet 23,076,914 L.L
L01EA03 TASIGNA B Nilotinib - 150mg 150mg Capsule 323,961,910 L.L
L01EB02 TARESSA 150 G Erlotinib (HCl) - 150mg 150mg Tablet, film coated 98,617,813 L.L
N03AX18 TREPADIO G Lacosamide - 150mg 150mg Tablet, film coated 7,555,604 L.L
N02AX02 TRAMAL RETARD B Tramadol HCl - 150mg 150mg Tablet, modified release 356,118 L.L
L01FD01 TRAZIMERA BioTech Trastuzumab - 150mg 150mg Injectable powder for solution 28,550,630 L.L
L01EA03 TASIGNA B Nilotinib - 150mg 150mg Capsule L.L
C09CA03 TABUVAN G Valsartan - 160mg 160mg Tablet, film coated 544,256 L.L
N05AX13 TREVICTA B Paliperidone - 175mg 175mg Injectable suspension, prolonged release 35,006,953 L.L
L01FF05 TECENTRIQ BioTech Atezolizumab - 1875mg/15ml 1875mg/15ml Injectable solution 375,054,619 L.L
R03BB04 TIOVA-T G Tiotropium bromide monohydrate - 18mcg 18mcg Rotacaps 384,339 L.L
J01DD04 TRAVILAN IM G Ceftriaxone (sodium) - 1g 1g Injectable lyophilised powder for solution+diluent 438,093 L.L
J01DD04 TRIAXONE G Ceftriaxone (sodium) - 1g, Lidocaine - 1% 1g Injectable powder for solution+diluent 438,093 L.L
    5
    ...
Sitemap
© Copyrights reserved to Ministry of Public Health 2025